Doctors called it “huge for patients,” if true. Patients who’ve struggled to afford the pricey medicines shared hope the price could be reached. Stocks of Novo Nordisk and Eli Lilly fell significantly.

Weight-loss surgery dramatically outperformed GLP-1 medications in improving longevity and reducing heart, kidney, and eye complications for people with obesity and diabetes. Over 10 years, patients lost far more weight and required fewer medications.

CMS Administrator Mehmet Oz clarified that a deal has not yet been sealed with the manufacturer of semaglutide, Novo Nordisk, or any other GLP-1 drugmaker.

Trump told reporters late Thursday that the list price of Ozempic, which he called “the fat loss drug,” will be “much lower.”

Semaglutide, tirzepatide, and other GLP-1 drugs appear to slow alcohol absorption and blunt its intoxicating effects, according to new research. The study found participants on these medications felt less drunk despite consuming the same amount of alcohol.

The increasing popularity of weight loss drugs like Wegovy, Ozempic, Mounjaro and metformin may have you wondering how all these options stack up. Are there benefits

Weight-loss drugs such as Ozempic first burst onto the scene after a landmark discovery in the treatment of type 2 diabetes. Then, they were championed as a way to combat levels of obesity. Now, companies are flooding the market with advertisements fixated on fat loss,

Novo Nordisk’s weekly injection for type 2 diabetes, Ozempic, is set to launch in India. Here’s how it works, its benefits, risks, and impact on weight loss.

Managing type 2 diabetes requires more than just taking a pill. It is a daily commitment to keeping blood sugar levels in check, reducing long-term risks, and maintaining overall well-being. In recent years, Ozempic has emerged as a widely discussed ...

Across the US, roughly 1 in 10 adults struggle with alcohol use disorder — a medical condition that makes quitting feel nearly impossible, even when it damages relationships, jobs and health. For the study,